Literature DB >> 11823118

Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications.

Meyoung-kon Kim1, Hyeh-Jean Jeong, Chih-Hao K Kao, Zhengsheng Yao, David S Paik, Jae Eun Pie, Hisataka Kobayashi, Thomas A Waldmann, Jorge A Carrasquillo, Chang H Paik.   

Abstract

This study was undertaken to improve the renal clearance and tumor targeting properties of 99mTc-labeled humanized anti-Tac (HuTac) monoclonal antibody Fab fragments using two chemical approaches: 1) labeling with a renal secretion agent 99mTc-mercaptoacetyltriglycine (MAG3) and 2) lowering its isoelectric point (pI) by acylation. HuTac Fab (3.3 mg/mL) was reacted with a trifluorophenyl ester (TFP) of 99mTc-MAG3 alone or was additionally reacted with TFP-glycolate to reduce the pI. In Balb/c mice, 99mTc-MAG3-Fab (pI > 9.3) rapidly accumulated in the kidneys (177% injected dose [ID]/g at 15 min) and then gradually cleared out of the kidneys. In contrast, the glycolation (pI 4.6 approximately 6.6) drastically reduced the renal uptake (31% ID/g) and also the whole-body retention (82% ID vs 101% for the nonglycolated) at 15 min, indicating that the glycolated 99mTc-MAG3-Fab (pI 4.6 approximately 6.6) was rapidly excreted. The glycolated remained in the blood longer than the nonglycolated (1.2% vs 0.3% ID/g at 360 min), but this effect was less drastic than the effect shown on the renal uptake. In nude mice bearing receptor-positive (ATAC4) tumors, the glycolated 99mTc-MAG3-Fab increased the peak tumor uptake to 14.8% ID/g from 8.3% ID/g for 99mTc-MAG3-Fab, whereas the glycolation resulted in a drastic reduction of the renal uptake at 15 min. We demonstrated that the renal clearance and the tumor targeting of Fab could be optimized by chemical modifications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823118     DOI: 10.1016/s0969-8051(01)00296-7

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

1.  Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert L Vessella
Journal:  Bioconjug Chem       Date:  2011-05-05       Impact factor: 4.774

2.  Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

Authors:  Torun Engfeldt; Anna Orlova; Thuy Tran; Alexander Bruskin; Charles Widström; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

3.  Optimization modeling of single-chain antibody against hepatoma based on similarity algorithm.

Authors:  Zhi-Jun Zhao; Jing-Tao Chen; Jia-Ying Yuan; Xiao-Xiang Yin; Hua-Yong Song; Xin-Chun Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Renal-Clearable PEGylated Porphyrin Nanoparticles for Image-guided Photodynamic Cancer Therapy.

Authors:  Liang Cheng; Dawei Jiang; Anyanee Kamkaew; Hector F Valdovinos; Hyung-Jun Im; Liangzhu Feng; Christopher G England; Shreya Goel; Todd E Barnhart; Zhuang Liu; Weibo Cai
Journal:  Adv Funct Mater       Date:  2017-07-26       Impact factor: 18.808

Review 5.  scFv antibody: principles and clinical application.

Authors:  Zuhaida Asra Ahmad; Swee Keong Yeap; Abdul Manaf Ali; Wan Yong Ho; Noorjahan Banu Mohamed Alitheen; Muhajir Hamid
Journal:  Clin Dev Immunol       Date:  2012-03-15

6.  Novel single-chain variant of antibody against mesothelin established by phage library.

Authors:  Hiromasa Yakushiji; Kazuko Kobayashi; Fumiaki Takenaka; Yoshiro Kishi; Midori Shinohara; Masaru Akehi; Takanori Sasaki; Eiji Ohno; Eiji Matsuura
Journal:  Cancer Sci       Date:  2019-08-28       Impact factor: 6.716

Review 7.  Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy.

Authors:  Paola Muñoz-López; Rosa María Ribas-Aparicio; Elayne Irene Becerra-Báez; Karla Fraga-Pérez; Luis Fernando Flores-Martínez; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.